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In Europe, the species Lactobacillus rhamnosus is currently on the Qualified Presumption of Safety list used by the European Food Safety Auth-
ority (EFSA) for internal safety assessment, but according to the EFSA the species should remain a topic of surveillance. In the present study, the
safety and tolerance of the potentially probiotic strain L. rhamnosus PRSF-L477 was investigated in a placebo-controlled double-blind volunteer
trial following FAO/WHO guidelines. A total of thirty-four subjects received daily doses of 1 £ 1011 colony-forming units (cfu) of L. rhamnosus
PRSF-L477 (n 17) or placebo (n 17) for a period of 3 weeks, followed by a wash-out period of another 3 weeks. A questionnaire on gastrointestinal
tolerance and a diary was kept daily to record compliance throughout these 6 weeks. Faecal and blood samples were collected for microbiological
and haematological analysis. The recorded gastrointestinal symptoms, defecation frequency and stool consistency were not influenced indicating
that L. rhamnosus PRSF-L477 was well tolerated. The species L. rhamnosus was detected in the faeces of sixteen out of seventeen subjects of the
probiotic group during the intervention period. Using pulsed-field gel electrophoresis, re-isolates of L. rhamnosus PRSF-L477 were confirmed in
nine of these subjects. Antibiotic susceptibility profiles of these re-isolates were unchanged compared with PRSF-L477. No clinically relevant
changes in blood parameters such as liver and kidney function and no serious adverse events appeared during and after administration. Therefore,
we conclude that L. rhamnosus PRSF-L477 can safely be administrated to healthy subjects at a daily dose of 1 £ 1011 cfu.
Lactobacillus rhamnosus: Safety: Probiotics: Colonisation: Re-isolation: Antibiotic susceptibility
Lactobacilli are commensal lactic acid bacteria of the human
and animal gastrointestinal tract, but are also used worldwide
as starter cultures in the production of dairy foods and as pro-
biotics. Due to their long history of safe use in food appli-
cations, their very low pathogenicity and the low frequency
of isolation from blood cultures, lactobacilli are generally
regarded as safe in healthy subjects(1,2). However, in a
number of rare cases in immunocompromised patients or sub-
jects with underlying diseases, Lactobacillus strains have been
associated with cases of clinical infections such as bacteraemia
and endocarditis. Lactobacillus rhamnosus and L. paracasei
were most commonly isolated from such infections(3 – 5).
So far, a possible epidemiological link between probiotic con-
sumption and rise in clinical isolates of lactobacilli has not
been clearly established(6). Nonetheless, several reports have
linked infections directly to the consumption of probiotic pro-
ducts(7 – 10), but clinical trials and intervention studies have so
far not indicated any safety problems with L. rhamnosus GG,
LC705 or HN001(11 – 14). However, conflicting results have
been reported on the potential role of commensal lactic acid
bacteria and bifidobacteria as vectors of antibiotic resistance
elements in food and intestinal environments, which has trig-
gered an ongoing debate(15 – 18). As such, the fate of probiotic
strains during gastrointestinal transit in an antibiotic-contain-
ing environment has previously been studied(19). In the latter
study a higher proportion of tetracycline-resistant anaerobi-
cally growing bacteria and bifidobacteria was detected in the
antibiotic group compared with the control group. Several
antibiotic-challenged subjects had faecal Bifidobacterium
animalis subsp. lactis Bb-12-like isolates with reduced tetra-
cycline resistance, which was, however, unlikely due to the
acquisition of novel tetracycline resistance determinants.
Recently, it has also been shown that a probiotic Lactobacillus
strain can acquire vancomycin resistance during a digestive
transit in mice(20).
It has been recommended by the European Food Safety
Authority that L. rhamnosus remains in the Qualified
Presumption of Safety list, but that this species should be
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considered a topic of regular surveillance(21). In their
recommendations on biosafety assessment of probiotics used
for human consumption based on the results of the European
Union PROSAFE (Biosafety Evaluation of Lactic Acid
Bacteria used for human consumption) project, participants
from academics and industry recognised the relevance of
human colonisation studies in a randomised placebo-
controlled double-blind design, but did not specify which par-
ameters should be determined in such studies(22). For instance,
limited attention has been given to the stability of a probiotic
strain after passage through the gastrointestinal tract.
Colonisation, but not stability, of L. rhamnosus strains has
been studied through re-isolation from faecal samples(23 – 26).
In the present study, a placebo-controlled double-blind
human volunteer trial was organised to investigate the toler-
ance and safety of a potentially probiotic L. rhamnosus
strain, PRSF-L477, following WHO/FAO guidelines(27).
The study was performed as a part of the European Union
PROSAFE project on the biosafety evaluation of lactic acid
bacteria for human consumption. PRSF-L477 has been
proposed to modulate dendritic cell function to induce a
novel form of T cell responsiveness. An anti-inflammatory
mechanism of PRSF-L477 has been proposed and therefore
it may be of interest for the treatment of a variety of inflam-
matory disorders(28). PRSF-L477 may also be of benefit in
the preservation of gut barrier integrity after injury or stress,
as has been shown previously in a rat model for haemorrhagic
shock(29). From the host’s perspective, evaluation of tolerance
and safety in the present study was based on questionnaires,
blood safety parameters and the number and type of
adverse events. Also, colonisation and wash-out kinetics of
L. rhamnosus PRSF-L477 were determined, and the pheno-
typic and genotypic stability of faecal re-isolates of this
strain from healthy subjects was assessed.
Experimental methods
Study population
A total of thirty-six healthy volunteers were enrolled in the
study using the following exclusion criteria: pregnancy and
breast-feeding; blood parameters outside the normal range
and considered clinically significant; history of metabolic or
gastrointestinal disease; food allergies; recent use of anti-
biotics or laxative drugs; diarrhoea; constipation; diabetes
mellitus; blood pressure . 150/90 mmHg. The inclusion
criteria were: healthy male or female; age 18–60 years;
normal defecation pattern; blood parameters within the
normal range or not considered clinically significant if outside
the normal range; BMI 18·0–29·9 kg/m2; written informed
consent.
Trial design
The study was a randomised, placebo-controlled, double-
blind, parallel-group study. The study was conducted accord-
ing to guidelines laid down in the Declaration of Helsinki and
all procedures involving human subjects were approved by the
ethics review committee of the Institutional Review Board
Nijmegen (The Netherlands). After having signed informed
consent, subjects were screened for eligibility into the study.
Subjects taking probiotic preparations were asked to enter a
3-week wash-out period before screening (Fig. 1). Subjects
eligible for participation (n 36) were randomly allocated to
receive either the probiotic or the placebo product after strati-
fication for age (,40 years and . 40 years). Subjects were
instructed to take the product for a period of 3 weeks, fol-
lowed by a wash-out period of another 3 weeks. Faecal
samples were collected weekly throughout these 6 weeks,
whereas a blood sample was taken at screening and after
3 weeks. Questionnaires were filled out after 3 and 6 weeks.
A diary was kept daily from screening onwards until the end
of the study. A double data entry procedure was used. The
study was conducted between September 2005 and December
2005 by the former Menox B.V., currently known as Ampha
B.V. (Nijmegen, The Netherlands). Regular quality checks
were performed by the study monitor.
Study parameters
The primary objective of the study was to assess the stability
of L. rhamnosus PRSF-L477 in the gut of healthy subjects.
The secondary objective was to assess the gastrointestinal
tolerance and safety of L. rhamnosus PRSF-L477. Sample
size was calculated based on the primary study parameter.
Product description
The probiotic study product contained lyophilised L. rhamnosus
PRSF-L477 in a total daily dose of 1 £ 1011 colony-forming
Time: Informed consent
visit 1a
Screening
visit 1b
0 weeks
visit 2
1 week
visit 3
2 weeks
visit 4
3 weeks
visit 5
4 weeks
visit 6
5 weeks
visit 7
6 weeks
visit 8
Fill in diary on daily basis
Supplementation of placebo
Supplementation of probiotic LAB
n 36
n 18 
n 18 
3-week run-in
if applicable 3-week wash-out
Fig. 1. Study design. LAB, lactic acid bacteria; , stool sample; # , blood sample.
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units (cfu) (Numico Research Culture Collection, Wageningen,
The Netherlands). The probiotic product was provided
in sachets by Milupa GmbH (Fulda, Germany). Subjects
were instructed to take two sachets per d. Each sachet
contained 0·5 g lyophilised PRSF-L477 at 1 £ 1011 cfu/g
and was filled up with maltodextrin to 7·5 g in total. The
placebo product contained 7·5 g maltodextrin and was
designed to have a similar appearance and taste as the
probiotic product.
Microbiological determination
Faecal samples were analysed by plating appropriate dilutions
on blood reinforced clostridial agar (BRCA) for the total
number of anaerobic bacteria and Lactobacillus anaerobic de
Man–Rogosa–Sharpe (MRS) agar with vancomycin and
bromocresol green (LAMVAB) agar for the number of lacto-
bacilli(30,31). BRCA contains reinforced clostridial medium
(38 g/l) (Oxoid, Basingstoke, Hants, UK), agar bacteriological
(18 g/l) (Oxoid), vitamin K1 (three drops/l) (0·25 mg/g;
Pharmacy Churchill, Wageningen, The Netherlands), defi-
brinated sheep blood (50 ml/l) (bioTrading, Mijdrecht, The
Netherlands) and salt solution (40 ml/l) containing MgSO4
(0·2 g/l), CaCl2 (0·2 g/l), K2HPO4 (1·0 g/l), KH2PO4 (1·0 g/l),
NaHCO3 (10 g/l) and NaCl (2·0 g/l). LAMVAB contains
MRS (52 g/l) (Oxoid), L-cysteine-HCl (0·25 g/l) (Sigma-
Aldrich, St Louis, MO, USA), broomcresol green (0·025 g/l)
(Merck, Darmstadt, Germany), agar bacteriological (20 g/l)
(Oxoid) and vancomycin-HCl (20 mg/l) (Pharmacy Churchill,
Wageningen, The Netherlands). The number of L. rhamnosus
was determined on modified LAMVAB, in which glucose was
substituted by rhamnose and the antibiotics kanamycin and
colistin sulfate (both 62 mg/l) were added. Only the species
L. rhamnosus and a few other Lactobacillus species that are
less common or even not present in the human gastrointestinal
tract are able to grow on this medium(32). The total number of
bacteria was determined with fluorescent in situ hybridisation
as previously described(33). The pH of the faecal samples was
measured to determine the influence of PRSF-L477 sup-
plementation on faecal pH values.
Re-isolation procedure
Faecal samples were plated on modified LAMVAB agar plates
for re-isolation of L. rhamnosus PRSF-L477. Five to ten colo-
nies grown on the modified LAMVAB medium from plated
faecal samples, preferably as late as possible in the study,
were picked and their identity was determined with quantita-
tive real-time PCR (qPCR) specific for L. rhamnosus (34) and a
qPCR specific for L. rhamnosus cluster VII (PRSF-L477 and
closely related L. rhamnosus (35)). The MGB-Taqman probe
used for L. rhamnosus cluster VII was prepared by Biolegio
(Malden, The Netherlands) (CCT GGA CAC ACG AAA);
primers used were the same as described earlier by Haarman
& Knol for L. rhamnosus (34). The species identity of the
re-isolates obtained from the probiotic group and positive
for the cluster VII qPCR was confirmed with 16S rDNA
sequencing (Baseclear, Leiden, The Netherlands) and strain
identity by PFGE.
Characterisation of PRSF-L477 re-isolates
The original strain PRSF-L477 and a selection of re-isolates
were subjected to pulsed-field gel electrophoresis (PFGE)
using Not I as a restriction enzyme according to the protocol
of Vancanneyt et al.(35). All isolates were analysed twice
with PFGE analysis. Conversion, normalisation and analysis
of the band patterns were performed using Bionumerics
software version 4.01 (Applied Maths, Sint-Martens Latem,
Belgium). Correlation coefficients and levels of similarity
were calculated using the Dice coefficient and cluster analysis
using the unweighted pair group method.
Antibiotic susceptibility
The susceptibilities of the original strain PRSF-L477 and a
selection of re-isolates to nineteen antimicrobials were tested
by determination of minimal inhibitory concentrations in
broth microdilution using LSM broth, which is a mixture of
IsoSensitest broth (90 %) and de Man–Rogosa–Sharpe broth
(10 %) adjusted to pH 6·7 and supplemented with L-cysteine
hydrochloride (0·3 g/l)(36).
Platelet aggregation
Aggregation was measured in an aggregometer (Payton
Lumi-aggregometer module series 100B; Payton Scientific,
Buffalo, NY, USA), by changes in the transmission of the
platelet suspension. Standard buffy coat-derived platelet
concentrates in plasma were prepared at Sanquin Research
(Amsterdam, The Netherlands) from whole blood units col-
lected by Sanquin Blood Bank and pooled from five different
donors. Bacterial strains were used as liquid stationary phase
cultures in PBS at pH 6·7. The platelet concentrates were
diluted with plasma to a concentration of 2·5 £ 108 cells/ml.
For the various tests, 10 % (v/v) of a bacterial suspension at
a concentration of 2·5 £ 109 cells/ml was added. The aggrega-
tion curve was followed for 25 min as previously described(37).
Gastrointestinal tolerance and safety parameters
Gastrointestinal tolerance was determined with the Gastroin-
testinal Symptom Rating Scale (GSRS)(38), the King’s Stool
Chart for stool consistency(39), the daily recorded gastroin-
testinal symptoms of nausea, vomiting, diarrhoea, burping,
abdominal distension and flatulence(40) and the defecation
frequency. The GSRS and stool consistency were measured
by the investigator at baseline and after 3 and 6 weeks. Pro-
duct compliance was recorded daily in a diary. Intolerance
was defined as a symptom score of 2 or higher (moderate or
severe) on the GSRS. Safety parameters were the number
and type of adverse events recorded throughout the whole
study and a change from baseline blood parameters deter-
mined at the end of the supplementation period. Measurement
of blood parameters was performed by a clinical laboratory
(Stichting Huisartsenlaboratorium Oost (SHO), Velp, The
Netherlands) and included haematological parameters (eryth-
rocyte sedimentation rate (mm/h), Hb (mmol/l), packed cell
volume (l/l), cholesterol (mmol/l), HDL-cholesterol (mmol/l),
glucose (mmol/l), mean corpuscular volume (fl) and leuco-
cytes ( £ 109/l)), and parameters for liver function (aspartate
R. D. Wind et al.1808
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aminotransaminase (IU/l), alanine aminotransaminase (IU/l),
g-glutamyl transferase (U/l)) and kidney function (creatinine
(mmol/l)).
Statistics
Statistical analyses of gastrointestinal symptom scores were
performed using the Mann–Whitney U test for equivalence.
Other parameters were tested for normal distribution with
homogeneous variance. Normally distributed parameters were
tested for statistically significant differences using the t test
or paired t test, while the Mann–Whitney U test or paired
Wilcoxon test was used for not normally distributed parameters.
Results
Subjects
A total of thirty-four subjects aged 18–60 years completed the
study, whereas two female subjects left the study group
prematurely because of antibiotic use (Fig. 2). Except for
the fact that more women than men participated in the study
(61 v. 39 %), subjects were well balanced over the two study
groups with respect to baseline characteristics such as age,
height, weight, BMI, heart rate and blood pressure (Table 1).
The median age for female and male subjects was 51 and
43 years, respectively, whereas the median age for the whole
study population was 47 years. Product compliance in the
Subjects screened
(n 39)
Subjects randomised
(n 36)
Not randomised
(n 3)
Reason:
– Screen failures
Active
(n 18)
Placebo
(n 18)
Completed
(n 17)
Early termination
(n 1)
Analysed ITT
(n 18) 
Analysed PP
(n 17)
Excluded from analysis:
– Protocol violation (n 1)
Analysed ITT
(n 18)
Analysed PP
(n 17)
Excluded from analysis:
– Protocol violation (n 1)
Early termination
(n 1)
Completed
(n 17)
Fig. 2. Flow chart of the study subjects. ITT, intention to treat; PP, per protocol.
Table 1. Baseline characteristics of the study groups (per-protocol population)
(Mean values and standard deviations)
Total group (n 34) Probiotic group (n 17) Placebo group (n 17)
Mean SD Mean SD Mean SD
Sex (n)
Male 14 8 6
Female 20 9 11
Age (years) 42 16 40 18 44 14
Height (m) 1·73 0·12 1·74 0·12 1·72 0·12
Weight (kg) 70·6 13·4 71·2 10·9 70·0 15·8
BMI (kg/m2) 23·5 3·1 23·6 3·0 23·4 3·3
Heart rate (beats/min) 63 11 61 12 66 8
Blood pressure (mmHg)
Systolic 120 13 118 11 121 16
Diastolic 75 7 73 7 76 7
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Table 2. Gastrointestinal symptom score according to the Gastrointestinal Symptom Rating Scale (GSRS) in the per-protocol population
(Median values and ranges)
GSRS symptom score*
Probiotic group Placebo group
Before
supplementation
After
supplementation After follow-up
Before
supplementation
After
supplementation After follow-up
Symptom Median Range Median Range Median Range Median Range Median Range Median Range
Abdominal pains (q1) 0 0 0–1 0 0–1 0 0 0
Heartburn (q2) 0 0–1 0 0–1 0 0–1 0 0–1 0 0–1 0 0–1
Acid regurgitation (q3) 0 0–1 0 0–1 0 0–1 0 0 0–1 0 0–1
Sucking sensations in the epigastrium (q4) 0 0 0–1 0 0 0 0–1 0
Nausea and vomiting (q5) 0 0–1 0 0–1 0 0–1 0 0–1 0 0
Borborygmus (q6) 0 0–1 0 0–1 0 0–1 0 0–1 0 0–2 0
Abdominal distension (q7) 0 0–1 0 0–1 0 0–1 0 0–1 0 0–1 0 0–1
Eructation (q8) 0 0–1 0 0–1 0 0–1 0 0–1 0 0–1 0 0–1
Loose stools (q12)† 0 0–1 0 0–1 0 0–1 0 0–1 0 0–1 0 0–1
Hard stools (q13)† 0·5 0–1 0 0–1 0 0–2 0 0 0–1 0 0–1
Urgent need for defecation (q14) 0 0–1 0 0–1 0 0–1 0 0–2 0 0–2 0 0–1
Feeling of incomplete evacuation (q15) 0 0–1 0 0–1 0 0–1 0 0–1 0 0 0–1
Dyspeptic syndrome (q1–5) 0 0–0·40 0 0–0·80 0 0–0·80 0 0–0·20 0 0–0·40 0 0–0·40
Indigestion syndrome (q6–8) 0 0–0·67 0 0–1·00 0 0–0·67 0 0–1·00 0 0–0·67 0 0–0·33
Bowel dysfunction syndrome (q12–15) 0 0–1·00 0·17 0–0·83 0 0–0·83 0 0–0·83 0 0–0·83 0 0–0·58
* 0 ¼ absent; 1 ¼ mild; 2 ¼ moderate; 3 ¼ severe.
† Either question (q) 12 or q 13 was answered.
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group of subjects included in the per-protocol analysis was
95–100 % for all subjects, except for one individual in the
placebo group who had a compliance of 90–95 %.
Gastrointestinal tolerance and safety parameters
Symptom scores as measured by the GSRS questionnaire were
all less than 2 and there was no significant difference between
the control group and supplemented group (Table 2). The
median score of the daily recorded gastrointestinal symptoms
of nausea, vomiting, diarrhoea, abdominal distension, burping
and flatulence did not change during the probiotic supple-
mentation period and the follow-up period. There were no
median scores of 2 or higher. Also, the stool consistency
and defecation frequency did not change during the sup-
plementation period and the follow-up period in both the pro-
biotic and placebo groups. No serious adverse events during
the supplementation period in either the placebo or probiotic
group were observed. In the probiotic group, sixteen adverse
events were reported, of which six were judged as possibly
related to the study product: increased flatulence (n 2), inter-
mittent abdominal cramps (n 1), more loose stools (n 1),
pain in the lower abdomen (n 1) and sensitive lower abdomen
minor pain (n 1). In the placebo group, twenty-seven adverse
events were reported, of which five were possibly related to
the study product: looser stools (n 4) and stinging pain in
the lower abdomen (n 1). In the GSRS questionnaire the
difference between the probiotic and placebo groups was not
significant on the symptoms of abdominal pains and loose
stools (Table 2).
Blood parameters for testing the safety of L. rhamnosus
PRSF-L477 administration were measured before and at the
end of the supplementation period. No clinically relevant
changes in blood safety parameters were found (Table 3).
Creatinine tended to decrease in the probiotic group and to
increase in the placebo group during the supplementation
period. These changes in creatinine concentration were not
considered to be clinically relevant by the medical study
monitor, as reference values used for adult men and women
were between 50 and 125mmol/l. Moreover, all creatinine
concentrations of individual subjects were within the reference
values ranging from 62 to 111mmol/l before and from 60 to
103mmol/l after supplementation. There were no significant
differences in the other blood parameters between the probio-
tic and placebo group before and at the end of the supplemen-
tation period.
Re-isolation of Lactobacillus rhamnosus PRSF-L477
L. rhamnosus PRSF-L477 was re-isolated from the collected
faecal samples. One faecal re-isolate from each subject of
the probiotic group (n 17) that was positive for L. rhamnosus
and for L. rhamnosus cluster VII-specific qPCR was further
identified with 16S rDNA sequencing. L. rhamnosus was
detected in the faeces of sixteen out of seventeen subjects of
the probiotic group during the supplementation and follow-
up period. This single non-responder was shown to be low in
lactobacilli and L. rhamnosus counts during the whole study
period. From these sixteen positive subjects, identification as
L. rhamnosus was confirmed by 16S rDNA sequencing for
twelve faecal re-isolates from eleven different subjects.
PFGE analysis indicated that nine out of these twelve re-
isolates exhibited fingerprints that were indistinguishable
from the profile of PRSF-L477 (Fig. 3). The remaining three
Table 3. Blood parameters in the per-protocol population
(Mean values with their standard errors)
Concentration
Probiotic group Placebo group
Before
supplementation
After
supplementation
Before
supplementation
After
supplementation
Blood parameter Mean SE Mean SE Mean SE Mean SE
Haematological
ESR (mm/h) 4 1 4 1 6 1 7 2
Hb (mmol/l) 8·9 0·2 8·9 0·2 8·9 0·2 8·9 0·2
Packed cell volume (l/l) 0·42 0·01 0·42 0·01 0·43 0·01 0·42 0·01
Liver function
ASAT (IU/l) 21 2 20 1 18 2 19 2
ALAT (IU/l) 24 4 24 4 24 3 26 4
g-GT (U/l) 24 2 23 3 23 3 24 4
Kidney function
Creatinine (mmol/l) 81 3 78* 3 80 3 82* 2
Other
Cholesterol (mmol/l) 5·2 0·3 5·2 0·3 5·2 0·3 5·1 0·3
HDL-cholesterol (mmol/l) 1·27 0·07 1·27 0·08 1·31 0·06 1·30 0·07
Cholesterol:HDL-cholesterol ratio 4·2 0·3 4·3 0·3 4·1 0·3 4·0 0·3
Glucose (mmol/l) 5·2 0·1 5·2 0·1 5·4 0·1 5·3 0·1
MCV (fl) 91 1 91 1 92 1 92 1
Leucocytes ( £ 109/litre) 5·4 0·3 5·4 0·2 5·8 0·4 5·8 0·4
ESR, erythrocyte sedimentation rate; ASAT, aspartate aminotransaminase; ALAT, alanine aminotransaminase, g-GT, g-glutamyl transferase;
MCV, mean corpuscular volume.
* Statistical trend between probiotic and placebo group with regard to before supplementation (P¼0·081; t test).
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isolates, i.e. 101-4D, 209-5C and 216-4D, showed a comple-
tely different PFGE profile compared with the administered
L. rhamnosus PRSF-L477, indicating that they were not
true re-isolates of PRSF-L477. No positive re-isolates of
L. rhamnosus PRSF-L477 were found in the faecal samples
of the probiotic group collected during the wash-out period.
In the placebo group re-isolates of L. rhamnosus were
detected by plating and qPCR in ten out of seventeen subjects;
these were, however, not further identified by 16S rDNA
sequencing or PFGE analysis.
Antibiotic susceptibility profiling
Antibiotic susceptibility profiling indicated that the three
isolates that displayed a completely different PFGE
profile compared with PRSF-L477 (i.e. 101-4D, 209-5C and
216-4D) also exhibited a different antibiotic susceptibility
profile (Table 4). The other nine re-isolates showed a highly
comparable if not identical antibiotic susceptibility profile to
PRSF-L477. Both the supplemented PRSF-L477 and re-isolate
110-4E were negative for platelet aggregation within 25 min.
Other re-isolates were not tested for platelet aggregation.
Colonisation and wash-out kinetics
The viable count of total anaerobic bacteria, lactobacilli and
the species L. rhamnosus was determined by plating on
respectively BRCA, LAMVAB and modified LAMVAB
agar, before and during the supplementation period and
40 60 80 10
0
211-2A
201-4C
202-4A
PRSF-L477
208-4D
110-4E
113-2E
113-2E
211-2A
201-4C
209-4B
PRSF-L477
202-4A
208-4D
113-2E
110-4E
218-4E
218-4E
221-4E
101-4D
101-4D
209-5C
209-5C
216-4D
216-4D
Fig. 3. Pulsed-field gel electrophoresis (Not I) profiles of Lactobacillus
rhamnosus PRSF-L477 and its faecal re-isolates after gastrointestinal tract
passage. The designation code of the re-isolates comprises information on
subject number, sample number and colony number, respectively.
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1 week after the end of the supplementation period (Table 5).
During the supplementation period, the number of lactobacilli
and L. rhamnosus in the faeces showed a significant increase
in the probiotic group (P,0·05; paired t test). In the placebo
group both the number of lactobacilli and L. rhamnosus
decreased during the supplementation period. This decrease
was non-significant except for the number of lactobacilli
in the faecal samples after 3 weeks compared with the
start of the study (paired Wilcoxon test). There was already
a significant difference in the number of L. rhamnosus
between the probiotic and the placebo group after 1 week of
supplementation (P¼0·012; t test). During the follow-up
period, the number of lactobacilli and L. rhamnosus decreased
to initial levels in the probiotic group within 1 week after
supplementation had stopped, while in the placebo group
counts remained stable at the lower levels found in week 1.
There were no significant differences in the total number of
bacteria determined by fluorescent in situ hybridisation as
median values ranged from 10·7 to 10·9 log cfu/g wet faeces
with a standard deviation of 0·2–0·3 (P.0·05; t test). There
were also no significant differences in the total number of
anaerobic bacteria determined by plating between the pro-
biotic and placebo groups at any time point during the study
(P.0·05; Mann–Whitney U test). The pH of the faeces did
not change during the supplementation period and the
follow-up period in both the probiotic and placebo groups
(data not shown).
Discussion
In the present study, the tolerance, safety, colonisation and
stability of the potential probiotic strain L. rhamnosus
PRSF-L477 were investigated in healthy volunteers.
Administration of a daily dose of 1 £ 1011 cfu L. rhamnosus
PRSF-L477 was safe and well tolerated in the population
tested. The recorded gastrointestinal symptoms (GSRS and
daily recorded symptoms), defecation frequency and stool
consistency were not influenced. No clinically relevant
changes in blood parameters and no serious adverse events
appeared during and after administration. In addition, it has
been suggested that the safety of probiotics should be tested
by the detection of undesirable changes in immune para-
meters(41) or unwanted changes in harmful faecal enzyme
activities(42). These tests were not included in the present
study, indicating that various other parameters may need
to be included in both short-term and long-term safety evalu-
ations before applying new L. rhamnosus strains in more
vulnerable target populations such as, for example, severely
immune-compromised individuals.
The administered strain L. rhamnosus PRSF-L477 was re-
isolated from nine subjects in the probiotic group during the
supplementation period. The PFGE and the antibiotic suscep-
tibility profiles of the faecal re-isolates remained virtually
unchanged compared with the originally administered strain
during passage through the gastrointestinal tract of healthy
subjects. Solely based on antibiotic susceptibility profiling of
nine faecal re-isolates, these data suggest that L. rhamnosus
PRSF-L477 was phenotypically stable during the study
period. In terms of risk assessment, more research including
a higher number of re-isolates would be needed to investigate
the possible transfer of resistance genes from the autochtho-
nous gut microbiota to strain PRSF-L477 in healthy volun-
teers. In another study where tetracycline susceptibility of
ingested L. acidophilus LaCH-5 and B. animalis subsp.
lactis Bb-12 during antibiotic-probiotic intervention was
investigated, oral tetracycline therapy resulted in increased
tetracycline resistance among faecal anaerobic bacteria inclu-
ding the ingested Bb-12 strain(19). When Bb-12-like isolates
were subcultured again without antibiotic selection, tetra-
cycline minimal inhibitory concentrations decreased but not
Table 5. Plate counts (log colony-forming units/g wet faeces) for the different bacterial groups
from faecal samples collected at several time points of the study for the entire population
(per-protocol population)
(Mean values and standard deviations)
t ¼ 0 weeks t ¼ 1 week t ¼ 3 weeks
Wash-out
(4 weeks)
Bacteria Mean SD Mean SD Mean SD Mean SD
Total anaerobic count (BRCA)
Probiotic group 8·7 0·7 8·7 0·4 8·5 0·5 8·5 0·6
Placebo group 8·4 0·5 8·4 0·7 8·5 0·6 8·6 0·6
Lactobacilli (LAMVAB)
Probiotic group 3·6 1·3 4·5* 1·1 4·5* 1·1 3·7‡ 1·7
Placebo group 4·2 1·0 3·8† 1·6 3·6§ 1·2 3·7k 1·1
Lactobacillus rhamnosus (modified LAMVAB)
Probiotic group 3·0 1·4 4·0* 1·0 3·9* 1·4 3·1‡ 1·6
Placebo group 3·5 1·4 3·1† 1·6 3·0† 1·4 3·1{ 1·2
BRCA, blood reinforced clostridial agar; LAMVAB, Lactobacillus anaerobic MRS agar with vancomycin and
bromocresol green.
* Significant difference compared with t ¼ 0 weeks (P,0·05; paired t test).
† Non-significant difference compared with t ¼ 0 weeks (P.0·05; paired Wilcoxon test).
‡ Non-significant difference compared with t ¼ 0 weeks (P.0·05), significant wash-out compared with t ¼ 3
weeks (P,0·05) (paired Wilcoxon test).
§ Significant difference compared with t ¼ 0 weeks (P,0·05; paired Wilcoxon test).
kNon-significant difference compared with t ¼ 0 weeks (P.0·05; paired Wilcoxon test), non-significant
difference compared with t ¼ 3 weeks (P.0·05; paired t test).
{Non-significant difference compared with t ¼ 0 and t ¼ 3 weeks (P.0·05; paired Wilcoxon test).
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to the original level. From the study it was, however, not
possible to say whether this was due to changes that had
occurred in the tet(W) gene or to its regulation in these
isolates during antibiotic therapy.
In a previous study, a set of 118 L. rhamnosus strains
intended for probiotic use and isolates of human origin were
genotypically characterised using amplified fragment length
polymorphism (AFLP) and PFGE(35). Numerical analyses of
AFLP patterns assigned L. rhamnosus PRSF-L477 to cluster
VII, which was the largest cluster found in that study contain-
ing one commercial probiotic strain, two potentially probiotic
strains, two food strains and forty-five human isolates, inclu-
ding thirty isolates from sterile sites and fifteen from commen-
sal flora. PRSF-L477 grouped closely to L. rhamnosus LMG
6400T ¼ American Type Culture Collection (ATCC) 7469T.
Previously, two morphological mutants of L. rhamnosus
ATCC 7469 were shown to exhibit increased platelet aggrega-
tion after gastrointestinal passage in gnotobiotic rats(43). Plate-
let aggregation is a factor contributing to virulence and
suggested to contribute to the progression of infective endo-
carditis(43). In the present study, however, strain PRSF-L477
and one of its re-isolates were negative for platelet aggrega-
tion. In order to confirm that platelet aggregation of PRSF-
L477 after passage through the gastrointestinal tract is not
affected, more re-isolates should be included in this assay.
The viable count of L. rhamnosus increased in the faeces
during supplementation with strain PRSF-L477, but it
decreased rapidly after the end of the supplementation
period. These findings suggest that PRSF-L477 does not colo-
nise the gastrointestinal tract of healthy subjects and is washed
out quickly after supplementation ends. This was also con-
firmed by the fact that PRSF-L477 re-isolates were not recov-
ered during the 3-week wash-out period. Supplementation
with L. rhamnosus PRSF-L477 did not appear to influence
the total number of bacteria and the total number of anaerobic
bacteria, but, as expected, it did influence the total number of
lactobacilli. The number of lactobacilli increased during
PRSF-L477 supplementation but decreased again when
supplementation stopped. Studies on intestinal colonisation
of L. rhamnosus reported similar results showing that
the administered strains could easily be recovered during the
intervention period but were washed out quickly during
the post-administration period(24). Re-isolates were only
recovered from a few subjects after 1 week but were not
detected after 2 weeks except for rare cases where re-isolates
of the strain were detected after a few months.
Initial counts for lactobacilli were 1–2 log10 levels lower
compared with plating results for lactobacilli in previous
studies in human healthy volunteers(24,44), which might be
due to differences in media composition or handling of
faecal samples. The initial higher counts for the placebo
group compared with the probiotic group for both lactobacilli
and L. rhamnosus were not due to differences in base-
line characteristics as these were equally divided over the
two study groups. The small age difference between the two
groups was non-significant (Mann–Whitney U test). The higher
initial counts for both lactobacilli and L. rhamnosus in the
placebo group were lost during the study. This loss was,
however, non-significant with the exception of t ¼ 3 weeks
compared with t ¼ 0 weeks for the lactobacilli in the placebo
group (P¼0·015; paired Wilcoxon test). As no intake of
probiotic products was allowed during and 3 weeks before
the study, a decrease in probiotic consumption in the
placebo group was not likely to be the cause of this loss but
cannot be excluded.
Conclusions
The results obtained in the course of a placebo-controlled
double-blind volunteer trial indicate that the potentially
probiotic strain L. rhamnosus PRSF-L477 is well tolerated
and does not induce serious adverse events during or after
administration. Therefore, it can be concluded that PRSF-
L477 can safely be administrated to healthy adult subjects at
a daily dose of 1 £ 1011 cfu. Over the entire study period,
nine re-isolates of this strain as confirmed by PFGE are phe-
notypically stable with regard to their antibiotic susceptibility
profile. The strain does not appear to colonise the gastro-
intestinal tract of healthy subjects and is washed out quickly
when supplementation ends. The present study thus provides
the basis for further analysis of the efficacy of L. rhamnosus
PRSF-L477 in a randomised double-blind placebo-controlled
design according to FAO/WHO guidelines.
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